Early diagnosis and prompt, appropriate clinical therapy for sepsis are critical to increasing survival chances. Antibiotic resistance significantly impacts the clinical responsiveness to treatment, leading to rapid disease progression in sepsis and septic shock. Addressing these factors swiftly can make a substantial difference in patient outcomes.
Time is of the essence!
The eazyplex® BloodScreen Gram-positive and Gram-negative panel allows you to detect the most common bacterial pathogens of sepsis and their associated antibiotic resistances. These factors strongly influence the disease outcome. With eazyplex®, you can obtain results directly from a positive blood culture without the need for DNA extraction, all within just 20 minutes.
Time is of the essence!
The eazyplex® BloodScreen Gram-positive and Gram-negative panel allows you to detect the most common bacterial pathogens of sepsis and their associated antibiotic resistances. These factors strongly influence the disease outcome. With eazyplex®, you can obtain results directly from a positive blood culture without the need for DNA extraction, all within just 20 minutes.
|
The eazyplex® BloodScreen
The most common parameters are available to you with the eazyplex® BloodScreen. There are two panels, one for the Gram-positive spectrum and one for the Gram-negative spectrum. The examination is carried out directly from the positive blood culture without DNA extraction.
All signals are displayed to you in real time during the amplification. The eazyplex® test system is a lyophilized, ready-to-use amplification system and can be stored directly at the workplace at room temperature. |
|
These four published evaluations, and many more evaluations, of the eazyplex®Blood Screen can be accessed at eazyplex® website-publications.
Here is an overview of comments from the Conclusions of these evaluations.
Direct use of eazyplex® SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections
PMC6506573 Istituto di Microbiologia(and other sources) Rome, Italy 2019
Conclusion: Our study shows that a rapid diagnostic-driven clinical strategy allowed for early prescription of potentially effective antimicrobial therapy in BSIs caused by CTX-M ESBL- and/or KPC/VIM carbapenemase-producing Ec and Kp organisms.
Performance of the eazyplex® BloodScreen GN as a simple and rapid molecular test for identification of Gram-negative bacteria from positive blood cultures
PMID: 34807364: Friedrich Schiller University, Jena, Germany 2022
In conclusion, the eazyplex® BloodScreen GN is a simple diagnostic tool for rapid BC testing. Because of the high accuracy in the identification of species and CTX-M genes, results can be used for a timely escalation of empiric therapy when indicated.
Assessment of a Multiplex LAMP Assay (Eazyplex® CSF Direct M) for Rapid Molecular Diagnosis of Bacterial Meningitis: Accuracy and Pitfalls
PMCID: PMC8471247 University Hospital of Nantes, France 021
Conclusions (abbreviated) Multiplex syndromic panels are easy to use and valuable additional tests to improve the timeliness of pathogen identification. However, this work underscores the fact that informed expertise on such automated approaches remains essential.
The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures
Antibiotics 2022, 11(2), 138; https://doi.org/10.3390/antibiotics11020138 2022
Conclusions The Eazyplex® SuperBug CRE assay can be a useful tool for a rapid and reliable identification of resistance mechanism genes in Gram-negative rods, and also directly from urine and pre-cultured blood samples.
Here is an overview of comments from the Conclusions of these evaluations.
Direct use of eazyplex® SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections
PMC6506573 Istituto di Microbiologia(and other sources) Rome, Italy 2019
Conclusion: Our study shows that a rapid diagnostic-driven clinical strategy allowed for early prescription of potentially effective antimicrobial therapy in BSIs caused by CTX-M ESBL- and/or KPC/VIM carbapenemase-producing Ec and Kp organisms.
Performance of the eazyplex® BloodScreen GN as a simple and rapid molecular test for identification of Gram-negative bacteria from positive blood cultures
PMID: 34807364: Friedrich Schiller University, Jena, Germany 2022
In conclusion, the eazyplex® BloodScreen GN is a simple diagnostic tool for rapid BC testing. Because of the high accuracy in the identification of species and CTX-M genes, results can be used for a timely escalation of empiric therapy when indicated.
Assessment of a Multiplex LAMP Assay (Eazyplex® CSF Direct M) for Rapid Molecular Diagnosis of Bacterial Meningitis: Accuracy and Pitfalls
PMCID: PMC8471247 University Hospital of Nantes, France 021
Conclusions (abbreviated) Multiplex syndromic panels are easy to use and valuable additional tests to improve the timeliness of pathogen identification. However, this work underscores the fact that informed expertise on such automated approaches remains essential.
The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures
Antibiotics 2022, 11(2), 138; https://doi.org/10.3390/antibiotics11020138 2022
Conclusions The Eazyplex® SuperBug CRE assay can be a useful tool for a rapid and reliable identification of resistance mechanism genes in Gram-negative rods, and also directly from urine and pre-cultured blood samples.
The Amplex eazyMini & eazyplex® open a door to a wide range of LAMP diagnostics, offering TATs under 30 minutes.
Memingitis, Septicaemia, C. difficile, MRSA, Candida auris, STI, Antibiotic Resistant Gram Negatives, EHEC, Vancomycin Resistance, Pneumocytis, Salmonella
Amplex eazyplex® is a molecular identification product range based on LAMP technology. The products have these common features;
- TATs under 30 minutes
- Ease of use, No DNA extraction
- Suitable for single or small numbers of tests
- Samples from urine, rectal swab (specified), blood culture (specified) and agar plate.
- Accuracy
|
The Manufacturer
Amplex Diagnostics GmbH is a German-based company founded in 2002 that specialises in providing rapid and robust CE-IVD tests to aid the diagnosis of microbiological infections. One of their products was the world's first MRSA multiplex PCR test to be CE IVD-certified for testing directly from sample material. Amplex makes the latest advanced technology available in a simple and user-friendly manner. Their eazyplex® system which can be operated intuitively, combines isothermal amplification (LAMP) with real-time detection. The eazyplex® reagents are supported by the eazyMini which enables isothermal amplification of all DNS and RNA targets in one compact device. It was specially developed for isothermal amplification assays with real-time detection based on fluorescence and enables reading of molecular diagnostics Real-time detection within a few minutes. www.eazyplex.com |
|
